Literature DB >> 7650340

Liver transplantation for hepatic arteriovenous malformation in hereditary haemorrhagic telangiectasia.

T Bauer1, P Britton, D Lomas, D G Wight, P J Friend, G J Alexander.   

Abstract

Symptomatic hepatic involvement is a rare complication of hereditary hemorrhagic telangiectasia and most commonly consists of fibrosis or cirrhosis. We describe a 33-year-old woman in whom multiple hepatic arteriovenous malformations led to high output cardiac failure and liver failure due to biliary necrosis with refractory biliary sepsis, requiring orthotopic liver transplantation. Hepatic arteriovenous malformations were the first manifestation of the disease and a similar asymptomatic hepatic tumour was subsequently detected in her 60-year-old father who also had the classical cutaneous stigmata of the syndrome. Unrecognised genetic factors may determine the clinical spectrum of hereditary haemorrhagic telangiectasia including the hepatic manifestations.

Entities:  

Mesh:

Year:  1995        PMID: 7650340     DOI: 10.1016/0168-8278(95)80455-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  9 in total

Review 1.  Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms.

Authors:  C L Shovlin; M Letarte
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  Successful liver transplantation for Rendu-Weber-Osler disease, a single centre experience.

Authors:  Murat Cag; Maxime Audet; Anne-Catherine Saouli; Murad Odeh; Bernard Ellero; Tullio Piardi; Marie-Lorraine Woehl-Jaeglé; Jacques Cinqualbre; Philippe Wolf
Journal:  Hepatol Int       Date:  2011-02-17       Impact factor: 6.047

3.  Clinical outcome of transfemoral embolisation in patients with arteriovenous malformations of the liver in hereditary haemorrhagic telangiectasia (Weber-Rendu-Osler disease).

Authors:  M Caselitz; S Wagner; A Chavan; M Gebel; J S Bleck; A Wu; H J Schlitt; M Galanski; M P Manns
Journal:  Gut       Date:  1998-01       Impact factor: 23.059

4.  Liver transplantation for hereditary hemorrhagic telangiectasia: Report of the European liver transplant registry.

Authors:  Jan Lerut; Giuseppe Orlando; René Adam; Carlo Sabbà; Robert Pfitzmann; Jurgen Klempnauer; Jacques Belghiti; Jacques Pirenne; Thierry Thevenot; Christian Hillert; Colin M Brown; Dominique Gonze; Vincent Karam; Olivier Boillot
Journal:  Ann Surg       Date:  2006-12       Impact factor: 12.969

5.  Hepatic artery embolization for treatment of patients with hereditary hemorrhagic telangiectasia and symptomatic hepatic vascular malformations.

Authors:  Ajay Chavan; Martin Caselitz; Karl-Friedrich Gratz; Joachim Lotz; Timm Kirchhoff; Plinio Piso; Siegfried Wagner; Michael Manns; Michael Galanski
Journal:  Eur Radiol       Date:  2004-08-17       Impact factor: 5.315

6.  Treatment of high output cardiac failure by flow-adapted hepatic artery banding (FHAB) in patients with hereditary hemorrhagic telangiectasia.

Authors:  A Koscielny; W A Willinek; A Hirner; M Wolff
Journal:  J Gastrointest Surg       Date:  2007-11-20       Impact factor: 3.452

7.  Liver cirrhosis in a patient with hepatic hereditary hemorrhagic telangiectasia and Budd-Chiari syndrome: a case report.

Authors:  Bai-Guo Xu; Jing Liang; Ke-Feng Jia; Tao Han
Journal:  BMC Gastroenterol       Date:  2020-06-03       Impact factor: 3.067

Review 8.  Hereditary haemorrhagic telangiectasia and pregnancy: a review of the literature.

Authors:  Olivier Dupuis; Laura Delagrange; Sophie Dupuis-Girod
Journal:  Orphanet J Rare Dis       Date:  2020-01-07       Impact factor: 4.123

Review 9.  Perioperative Complications and Long-Term Follow-Up of Liver Transplantation in Hemorrhagic Hereditary Telangiectasia: Report of Three Cases and Systematic Review.

Authors:  Antoni Riera-Mestre; Pau Cerdà; Yoelimar Carolina Guzmán; Adriana Iriarte; Alba Torroella; José María Mora-Luján; Jose Castellote; Amelia Hessheimer; Constantino Fondevila; Laura Lladó
Journal:  J Clin Med       Date:  2022-09-24       Impact factor: 4.964

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.